Objective To explore effects of nasal high flow oxygen therapy (HFNC) combined with high-pressure non-invasive positive pressure ventilation (NPPV) on inflammatory factors and lung function in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and type II respiratory failure.
Methods A retrospective analysis was conducted on the treatment of 90 patients with AECOPD combined with type II respiratory failure admitted to the Respiratory Department of Yixing Sixth People's Hospital from January 2022 to January 2025, among them, there were 47 males and 43 females; their ages ranged from 24 to 69 years, with an average of (46.82±7.61) years. The patients were divided into a control group and an observation group, with 45 patients in each group. The control group received high-pressure NPPV treatment, while the observation group received HFNC combined with high-pressure NPPV treatment. Comparative analysis of inflammatory factors [(C-reactive protein, CRP), (interleukin-17, IL-17), (tumor necrosis factor-α, TNF-α)], pulmonary function indicators [(forced vital capacity, FVC), (forced expiratory volume in the first second, FEV1), FEV1/FVC], and blood gas analysis indicators [(partial pressure of oxygen, PaO2), (partial pressure of carbon dioxide, PaCO2), pH] between two groups of patients upon admission and 3 days after treatment. The changes of CO2 and blood pH levels between the two groups, including length of hospital stay, intubation rate, readmission rate after 28 days of follow-up, and treatment efficacy were compared.
Results At admission, there was no significant difference in the levels of inflammatory factors CRP, IL-17, and TNF-α between the two groups (P>0.05); after 3 days of treatment, the CRP, IL-17, and TNF-α decreased in both groups of patients, the inflammatory factors CRP, IL-17, and TNF-α in the observation group were lower than those in the control group (P<0.05). At admission, there was no significant difference in the lung function indicators FVC, FEV1, and FEV1/FVC between the two groups (P>0.05); after 3 days of treatment, the FVC, FEV1, and FEV1/FVC of both groups of patients increased,and the lung function indicators FVC, FEV1, and FEV1/FVC in the observation group were higher than those in the control group (P<0.05). At admission, there was no significant difference in the blood gas analysis indicators PaO2, PaCO2, and pH value between the two groups (P>0.05); after 3 days of treatment, the PaO2 and pH values of both groups of patients increased significantly, while the PaCO2 values decreased significantly,the blood gas analysis indicators PaO2 and pH value in the observation group were higher than those in the control group, while PaCO2 was lower than that in the control group (P<0.05). The observation group had lower hospitalization days, intubation rate, and readmission rate due to the disease after 28 days of follow-up compared to the control group (P<0.05). The total effective rate of clinical treatment in the observation group was higher than that in the control group (P<0.05).
Conclusion The combination of HFNC and high-pressure NPPV in the treatment of AECOPD patients with type II respiratory failure can effectively improve lung function indicators, blood gas analysis indicators, reduce inflammatory reactions, and has good therapeutic effects, which is worth promoting.